GTH Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 mar 2024 @ 21:00):

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment...

Stats
Dagens volum	412 603
Gjennomsnittsvolum	51 864.00
Markedsverdi	127.29M
EPS	$0 ( 2024-01-18 )
Neste inntjeningsdato	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.110
ATR14	$0.00400 (0.10%)

Genetron Holdings Limited Korrelasjon

10 Mest positive korrelasjoner
VCTR	0.946
CLGN	0.946
ENTF	0.938
INCR	0.929
TZPS	0.927
VITL	0.924
FANG	0.923
ALSA	0.921
CITE	0.919
SVFAU	0.919

10 Mest negative korrelasjoner
NLSP	-0.931
HCDIP	-0.924
UONEK	-0.921
LUCD	-0.92
SHEN	-0.918
EMBC	-0.917
PEAR	-0.914
FRHC	-0.914
AKTX	-0.91
MVIS	-0.91

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Genetron Holdings Limited Økonomi

Annual	2022
Omsetning:	$650.71M
Bruttogevinst:	$281.43M (43.25 %)
EPS:	$-9.53

FY	2022
Omsetning:	$650.71M
Bruttogevinst:	$281.43M (43.25 %)
EPS:	$-9.53

FY	2021
Omsetning:	$531.95M
Bruttogevinst:	$337.97M (63.53 %)
EPS:	$-4.73

FY	2020
Omsetning:	$424.49M
Bruttogevinst:	$260.22M (61.30 %)
EPS:	$-50.90

Financial Reports:

No articles found.

Genetron Holdings Limited

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Sanntidsoppdatering for Genetron Holdings Limited [GTH]

Upcoming Earnings Alert